ARTICLE
11 April 2023

QUICK LOOK: What's Next For Opioid Litigation?

WL
WIT Legal

Contributor

WIT is the only expert witness agency representing the world's top consulting and testifying experts. By anticipating major trends in litigation, WIT proactively builds teams consisting of academic and industry experts who have the credentials and experience to address our client's needs.
The years-long, contentious wranglings of parties entangled in the National Prescription Opiate MDL looked to be winding down ...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

While opioid litigation has already crossed a wide swath of drugmakers, distributors, and dispensers, plaintiffs' attorneys aren't done yet and have set their sights on a new crop of defendants. Defense teams should assemble and mobilize experts to inform their legal strategies.

The years-long, contentious wranglings of parties entangled in the National Prescription Opiate MDL looked to be winding down, with the nation's largest pharmacy retailers offering settlements at the end of 2022. But while opioid litigation has already crossed a wide swath of drugmakers, distributors, and dispensers, plaintiffs' attorneys aren't done yet and have set their sights on a new crop of defendants. In their crosshairs are big supermarket chains with in-house pharmacies, a slew of second-tier drug manufacturing companies, and pharmacy benefits managers that were initially put to the side. What appears as a campaign against nearly the entire pharmaceutical industry and its partners is cause for alarm to many midsized pharmacies, manufacturers, and distributors not previously identified in the first wave of litigation. Some new and noteworthy defendants include big chains Albertsons Cos., Kroger Co., and Publix Super Markets, and benefits managers Express Scripts (Cigna Corp. unit) and OptumRx (UnitedHealth Group Inc.).

While plaintiffs' attorneys assess the fruitfulness of going to trial against these new targets, defense teams should begin to assemble and mobilize experts to inform their legal strategies, as the increased attention will likely cast a long shadow.

Aside from new frontiers in the MDL, opioid cases, in general, are becoming more decentralized, with suits brought by individual plaintiffs seeking damages for the vicissitudes of their lives. The unexpected ruling by the Judiciary Panel for Multidistrict Litigation last year stopped new cases from being added to the Opioid MDL, making the prospect of matters being filed in different federal courts throughout the country a likely outcome—a situation that could have defense counsel and clients rubbernecking at a breakneck pace to manage cases.

While the opioid litigation landscape evolves, the need for qualified experts remains. Consulting with experts with significant industry experience and specialized expertise in drug development, the duties and standards of pharmacists, the rules of processes of investigations, and the role of the DEA, can be crucial to defense teams. Specifically, it would be advantageous for defense counsel to retain former DEA diversion investigators, epidemiologists, economists, physicians, pharmacists, and FDA experts to inform and support their litigation strategies. In particular, we recommend that any defendant that handled controlled substances under a DEA license should line up experts on the anti-diversion and monitoring requirements as soon as possible. There is only a small group of people nationally who are properly qualified to analyze these issues and who are able to take on expert witness work. WIT has developed a series of relationships with former trainers and managers in the DEA's Diversion Investigation program that has allowed us to affiliate with these hard-to-find experts.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
11 April 2023

QUICK LOOK: What's Next For Opioid Litigation?

United States Food, Drugs, Healthcare, Life Sciences

Contributor

WIT is the only expert witness agency representing the world's top consulting and testifying experts. By anticipating major trends in litigation, WIT proactively builds teams consisting of academic and industry experts who have the credentials and experience to address our client's needs.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More